UY34078A - Composiciones farmacéuticas y métodos para tratar el cáncer - Google Patents

Composiciones farmacéuticas y métodos para tratar el cáncer

Info

Publication number
UY34078A
UY34078A UY0001034078A UY34078A UY34078A UY 34078 A UY34078 A UY 34078A UY 0001034078 A UY0001034078 A UY 0001034078A UY 34078 A UY34078 A UY 34078A UY 34078 A UY34078 A UY 34078A
Authority
UY
Uruguay
Prior art keywords
methods
pharmaceutical compositions
treat cancer
cancer
treat
Prior art date
Application number
UY0001034078A
Other languages
English (en)
Spanish (es)
Inventor
Rosen Oliver
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34078A publication Critical patent/UY34078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001034078A 2011-05-17 2012-05-17 Composiciones farmacéuticas y métodos para tratar el cáncer UY34078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486851P 2011-05-17 2011-05-17
US201161538246P 2011-09-23 2011-09-23

Publications (1)

Publication Number Publication Date
UY34078A true UY34078A (es) 2012-11-30

Family

ID=47177338

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034078A UY34078A (es) 2011-05-17 2012-05-17 Composiciones farmacéuticas y métodos para tratar el cáncer

Country Status (7)

Country Link
EP (1) EP2709614A4 (zh)
JP (1) JP2014513730A (zh)
AR (1) AR086444A1 (zh)
CA (1) CA2836277A1 (zh)
TW (1) TW201309291A (zh)
UY (1) UY34078A (zh)
WO (1) WO2012158884A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3124481B1 (en) 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
AU2011285724B2 (en) 2010-08-04 2015-01-22 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
AR083916A1 (es) * 2010-11-18 2013-04-10 Takeda Pharmaceutical Metodo para tratar el cancer de mama y cancer de ovarios
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2968219B1 (en) * 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
SG10201408699TA (en) * 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
AU2008319767B8 (en) * 2007-10-29 2014-01-09 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-C] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies

Also Published As

Publication number Publication date
EP2709614A4 (en) 2015-04-15
EP2709614A1 (en) 2014-03-26
WO2012158884A1 (en) 2012-11-22
JP2014513730A (ja) 2014-06-05
AR086444A1 (es) 2013-12-11
TW201309291A (zh) 2013-03-01
CA2836277A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
CL2018003282A1 (es) Métodos y composiciones para el tratamiento de cánceres resistentes a los inhibidores de la vía no erk mapk
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
CL2015001392A1 (es) Compuestos y sus métodos de empleo
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
BR112013028281A2 (pt) compostos e composições para inibição de nampt
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
CO7020912A2 (es) Inhibidores de bromodominios
BR112014001440A2 (pt) novas composições e métodos para o tratamento de câncer de próstata
BR112013025006A2 (pt) composições e métodos para inibição de expressão do gene tmprss6
EP2943565A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTRATION OF IMMUNE CELLS FOR TREATING TUMOR CELLS THAT ARE NOT RESTRICTED OR UNREQUIRED AND A TUMOR RECIPIENT
DK2707030T3 (da) Cancerbehandlinger
ES2579990T8 (es) Métodos y composiciones para tratar el síndrome metabólico
CO7151512A2 (es) Inhibidores del nampt
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
BR112015012907A2 (pt) composição de cuidado pessoal
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
GT201300045S (es) Aparato para peinar el cabello
HK1206387A1 (zh) 治療 相關疾病的有機組合物
BR112013008528A2 (pt) métodos para tratar psoríase
HK1216610A1 (zh) 用於經皮傳遞非類固醇消炎劑的組合物及方法
BR112015000099A2 (pt) composições e métodos para melhorar a mobilização e proliferação de células tronco similares a blastômeros
CR20130246A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019